Kancera
KAN | ST
Overview
Corporate Details
- ISIN(s):
- SE0015658570 (+1 more)
- LEI:
- 5493002P3RCOFW6HI207
- Country:
- Sweden
- Address:
- Nanna Svartz väg 4, 171 65 SOLNA
- Website:
- https://kancera.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Kancera is a pharmaceutical company that develops a new class of small-molecule drugs for life-threatening diseases with high medical needs. The company pioneers the development of drug candidates targeting the fractalkine axis (CX3CR1 antagonists) to precisely control disease-promoting immune cells and cancer cells. Its core focus is on treating severe inflammatory conditions and resistant cancers. Kancera's pipeline features two primary drug candidates, rugocrixan and fosrugocrixan, which are advancing through clinical trials for various indications.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Kancera.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| No filings match the current criteria. | ||||
Automate Your Workflow. Get a real-time feed of all Kancera filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Kancera via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
